Back to top
more

AbCellera Biologics (ABCL)

(Real Time Quote from BATS)

$2.83 USD

2.83
1,349,012

+0.10 (3.66%)

Updated Nov 4, 2024 12:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 13.33% and 27.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

GSK (GSK) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 9% and 4.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

AbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 12.50% and 11.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for AbCellera Biologics Inc. (ABCL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of 18.03% and 20.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of -4.76% and 1.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AbCellera Biologics Inc. (ABCL) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.

Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to Decline

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -3.77% and 0.27%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for October 26th

by Zacks Equity Research

GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 15.38% and 21.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 242.1% in AbCellera Biologics Inc. (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -16.67% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?

by Zacks Equity Research

Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.

Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie

by Zacks Equity Research

AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.

Implied Volatility Surging for AbCellera Biologics (ABCL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to AbCellera Biologics (ABCL) stock based on the movements in the options market lately.

AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Believe AbCellera Biologics Inc. (ABCL) Could Rally 138%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for AbCellera Biologics Inc. (ABCL) points to a 137.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.